- Home
- PHAR vs EOI Comparison
PHAR vs EOI Comparison
Compare PHAR & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EOI
- Stock Information
- Founded
- PHAR 1988
- EOI 2004
- Country
- PHAR Netherlands
- EOI United States
- Employees
- PHAR N/A
- EOI N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- PHAR Health Care
- EOI Finance
- Exchange
- PHAR Nasdaq
- EOI Nasdaq
- Market Cap
- PHAR 1.0B
- EOI 870.1M
- IPO Year
- PHAR N/A
- EOI N/A
- Fundamental
- Price
- PHAR $14.60
- EOI $21.46
- Analyst Decision
- PHAR Strong Buy
- EOI
- Analyst Count
- PHAR 3
- EOI 0
- Target Price
- PHAR $30.00
- EOI N/A
- AVG Volume (30 Days)
- PHAR 11.5K
- EOI 83.6K
- Earning Date
- PHAR 10-23-2025
- EOI 01-01-0001
- Dividend Yield
- PHAR N/A
- EOI 7.19%
- EPS Growth
- PHAR N/A
- EOI N/A
- EPS
- PHAR N/A
- EOI N/A
- Revenue
- PHAR $339,836,000.00
- EOI N/A
- Revenue This Year
- PHAR $16.63
- EOI N/A
- Revenue Next Year
- PHAR $6.77
- EOI N/A
- P/E Ratio
- PHAR N/A
- EOI N/A
- Revenue Growth
- PHAR 22.44
- EOI N/A
- 52 Week Low
- PHAR $7.06
- EOI $14.36
- 52 Week High
- PHAR $17.08
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- PHAR 57.37
- EOI 62.52
- Support Level
- PHAR $13.51
- EOI $21.40
- Resistance Level
- PHAR $15.61
- EOI $21.54
- Average True Range (ATR)
- PHAR 0.87
- EOI 0.16
- MACD
- PHAR -0.06
- EOI -0.01
- Stochastic Oscillator
- PHAR 59.37
- EOI 73.88
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.